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1.1 Bone morphogenetic proteins
Bone morphogenetic proteins (BMPs) are family of growth factors. (Chen et al., 2004;
Vukicevic & Sampath, 2008) Discovered in context of bone biology, today they are
recognized as important signaling molecules in wide range of biological processes, such
as vertebrate embryonic development (Hogan, 1996), mesenchymal stem cell differentiation
(Vukicevic & Grgurevic, 2009), kidney fibrosis, and more. For the last years BMP-2 and BMP-7
are used as therapeutics in orthopedics, harnessing their regenerative potential as growth
factors.
From the onset of medicine scholars have been aware of the bone regenerative potential.
In 1965. Urist was first to show that demineralized bone matrix (DBM) can induce bone
growth if implanted into extraskeletal site. Active component from DBM was named bone
morphogenetic protein by Urist & Strates (1971). Purification, cloning and sequencing of BMP
was done almost 20 years later by Wozney et al. (1988). They showed that BMP is not a single
protein but a family of growth factors.
From introduction of the BMP term through cloning and sequencing of individual BMPs in
late 1980s, scientific output in the field has constantly grown and has exceeded 1500 papers in
2010. (Figure 1)
BMPs are part of transforming growth factor (TGF- ) superfamily of proteins. In humans
TGF- superfamily constitutes of 37 proteins. (Figure 2) Beside BMPs, TGF- superfamily
includes TGF- proteins, inhibins (INH), growth/differentiation factors (GDF) and few others:
artemin (ARTN), glial cell line-derived neurotrophic factor (GDNF), left-right determination
factor 1 (LFTY1), LFTY2, muellerian-inhibiting factor (MIS), nodal homolog (NODAL),
neurturin (NRTN) and persephin (PSPN).
BMPs are functionally and structurally very conserved throughout animal kingdom. Their
biological importance is reflected through functional and structural redundancy of different
BMPs in single species. BMPs are translated as pre-propeptides. Signal peptide targets them
for secretion out of cell. Prodomain is two thirds to four fifths of total peptide length and
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Fig. 1. Scientific output on bone morphogenetic protein (solid black line), (mass spectrometry)
protein OR proteomics (dashed black line) and (mass spectrometry) AND bone morphogenetic
protein (green bars). Data gathered from Pubmed on June 2011.
Fig. 2. Transforming growth factor protein superfamily. Amino acid sequences were
aligned by ClustalW and plotted by Cytoscape with PhyloTree plugin.
is cleaved off to produce mature peptide chain. Mature domain is highly conserved and
has number of shared features. (Figure 3) There are seven conserved cysteines starting from
position 446 (by unified position numbering displayed above aligned sequences), and then on
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positions 475, 479, 511, 512, 545 and 547. Counting from first conserved cysteine there are 30
completely conserved positions which is almost one third length of mature domain.
From purification and sequencing studies done in late 1980s, it was clear that the active form
of a BMP is a homodimer made up of two mature domains connected by disulphide bridge.
The first BMP crystal structure was resolved by Griffith et al. (1996). Until present there are
more then 30 structures related to BMPs deposited into Protein Data Bank.
BMP mature domain is folded in the hand like structure. (Figure 4) Two fingers, made up of
two beta sheets, are protruding from the cystine knot, which is made up of three disulphide
bridges. On the opposite side of the cystine knot is alpha helix forming the heel of the hand.
Active homodimer is made up of two hand structures pointing in the opposing directions
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Fig. 3. BMPs sequence alignment. Ten most conserved BMPs aligned by ClustalW algorithm
with most conserved residues color coded by their physicochemical properties (Zappo color
scheme). Green sequence features are MS identified peptides deposited in PRIDE proteomics
database.
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Fig. 4. Crystal structure of the mature homodimer BMP6. (Saremba et al., 2008) One
monomer is cartoon rendered with sulfur atoms of cystine knot spacefill rendered. The
structure with 2R52 accession number was downloaded from Protein Data Bank, and
rendered by RasMol.
1.2 Mass spectrometry of proteins
Mass spectrometry (MS) of proteins exploded with the discovery of soft ionization techniques
in late 1980s. Fenn et al. (1989) produced one of the first mass spectra of different proteins
using electrospray ionization (ESI). They also introduced an algorithm for deconvolution of
multiple charged envelope in the mass spectra of proteins. Hillenkamp & Karas (1990) did a
similar thing with the matrix assisted laser dissociation ionization (MALDI).
Identification of proteins by peptide mass fingerprint (PMF) was introduced by Henzel et al.
(1993). Proteins, separated by two dimensional gel electrophoresis (2DE), are in gel protease
digested (usually by trypsin). Peptide masses are then measured by mass spectrometer.
The measured peptide mass fingerprint is used for searching the protein sequence database
by automated computer algorithm. The first large scale analysis using PMF was done by
Shevchenko et al. (1996). They identified 128 different yeast genes from 150 2D gel spots. This
scientific approach became proteomics after term proteome coined by Kahn (1995).
Protein identification is now done preferentially using tandem mass spectrometry. To avoid
errors and to speed up process, algorithms for the protein database searching using tandem
mass spectra of peptides had to be invented. (Eng et al., 1994; Perkins et al., 1999)
Except for the identification of proteins, mass spectrometry based quantification became
reality with development of isotope-coded affinity tag (ICAT) strategy. (Gygi et al., 1999)
After introduction, there have been devised different stable isotope labeling quantification
strategies. Ong et al. (2002) developed stable isotope labeling by amino acids in cell culture
(SILAC).
At last, proteomics community realized the importance of high mass resolving power, high
mass accuracy, scanning speed and dynamic range as crucial parameters on which number
and quality of the protein identifications depends. Mann & Kelleher (2008)
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2. Bone morphogenetic proteins by mass spectrometry
Before 2000 there were only two papers published reporting on separation of the glycoforms
of rhBMP-2 by capillary electrophoresis coupled to MS. (Yeung et al., 1997; Yim et al., 1995)
From 2000 onward, there is a continuum of scientific research on the BMPs using a mass
spectrometry. There are two main approaches to the research in the field: (a) isolation
and identification of a BMP or related molecule from different biological sources; and (b)
proteomic study of a system perturbed using a BMP or related molecule. We have reviewed
papers based on their biological focus.
2.1 Bone and cartilage
BMPs have been discovered and studied first as bone and cartilage growth factors. After
development and growth, bones are constantly remodeled to meet their body function.
Resorption of the bone is done by osteoclasts and formation by osteoblasts. Therapeutic
regeneration and skeletal tissue engineering depends on three elements: extracellular matrix,
cells and growth factors. (Reddi, 1998)
Role of BMP-1-3 in bone fracture repair has recently been studied in our group.
(Grgurevic et al., 2011) We have shown in vivo enhancement of bone healing by systemic
and local administration of BMP-1-3. We used rat fractured femur and critical size defect
of rabbit ulnae models and demonstrated a synergistic effect of BMP-1-3 and BMP-7 on bone
regeneration. BMP-1-3 stimulates osteoblast differentiation in vitro. By combining isolation
of growth factors with proteomic global approach we have identified potential biomarkers
of acute bone fracture from plasma of 25 patients. (Grgurevic et al., 2007) To overcome
inherent limitation of proteomics to cope with plasma protein dynamic range of more than
10 orders of magnitude, we have devised a growth factors enrichment strategy. Members
of TGF- protein superfamily have characteristic heparin binding domain as part of their
structure, and can be affinity enriched using heparin chromatography. We enriched growth
factors from 80 mL of pulled plasma, and than separeted them on minigel electrophoresis.
To overcome loading capacity of analytical gels, proteins were loaded into consecutive wells,
and afterwards combined in 12 fractions by electrophoretic mobility. After in-gel digestion,
peptides were separated and measured by on-line nano LC coupled to Orbitrap working
in data dependent scanning mode. Top five MS signals were isolated and fragmented by
CID in linear IT. Global proteomic approach allowed us to identify 213 proteins, of which
we have singled out 12 bone and cartilage related proteins. Four of them have never before
been found in the circulation: Transforming growth factor -induced protein ig-h3 ( ig-h3),
cartilage acidic protein 1 (CRTAC1), procollagen C proteinase enhancer protein (PCPE-1) and
TGF- receptor type 3 (TGF- -R-3). Nakasaki et al. (2008) have identified insulin-like growth
factor I(IGF-I) as potent chemotactic factor for osteoblasts and showed IGF-I involvement
in fracture healing. They used five step sequential chromatography to purify IGF-I from
18 L of MC3T3-E1 (mouse osteoblast-like cell line) serum free conditioned media (CM). After
precipitation of CM with 80% saturated ammonium sulphate, they used gelatine-, Blue-,
heparin-affinity chromatography, hydroxyapatite chromatography and gel filtration to purify
IGF-I more then 200 fold. IGF-I was separated by silver stained SDS-PAGE, in gel digested,
and measured by micro LC coupled to 3D IT working in data dependant mode.
Kim et al. (2009a) have studied transdifferentiation of murine premyoblast C2C12 cell line
induced by BMP-2. They invented the Two-Stage Double-Technique Hybrid (TSDTH)
proteomic strategy, for the analysis of early phosphoproteome and late proteome changes.
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Authors have enriched more then 150 g of phosphoproteins from 2 mg of the total protein
cell lysate using commercial kit. Using a phosphoprotein enrichment, as opposed to a
phosphopeptide enrichemnt, one should get a better sequence coverage of the individual
phosphorylated proteins. Phosphoproteins were separated by SDS-PAGE, in gel digested,
and analysed by micro LC coupled to linear IT. They measured MS3 fragmentation
spectra of phosphopeptides showing dominant neutral loss of phospho moiety (minus
98 Th/49 Th/32.7 Th for singly, doubly or triply charged species respectively) using data
dependant mode. For the proteome quantification, authors metabolically labelled all cell
proteins using SILAC approach. After combining samples, they separated proteins using
SDS-PAGE, in gel digested them, and analysed them by micro LC coupled to LTQ-FT working
in data dependent mode. Top five signals from high resolution survey scan were measured
individually using single ion monitoring (SIM) scan in FT-ICR analyser, and then CID
fragmented in linear IT. From 1321 phosphoproteins identified and 433 proteins quantified
authors selected 374 BMP-2 specific phosphoproteins and 54 differentially expressed proteins.
By pathway enrichment analysis authors found IGF and calcium signaling pathways as well
as TGF- /BMP signaling proteins to be potentially involved in the early and long-term actions
of BMP-2.
At present, BMP-2 and BMP-7 are the only BMPs commercially used for regenerative
purposes. We have identified lysine 60 of BMP-6 as amino acid crucial for BMP-6 lower
susceptibility to noggin inhibition in comparison to BMP-7. (Song et al., 2010) This is
important because of the present therapeutic use of BMP-7 in large doses. In BMP-6, lysine 60
forms intramolecular hydrogen bonds with asparagine 65 connecting finger 1 and 2 in that
way that it increases overall rigidity of the molecule.
Osteoporosis is one of the most prevalent bone disease. (Raisz, 2005) We have studied
effects of systemically administered BMP-6 to osteoporotic rats. (Simic et al., 2006) We
could not demonstrate the presence of BMPs in bone extract of ovariectomized rats.
We next demonstrated that systemically administered recombinant human mature BMP-6
accumulates in the skeleton. BMP-6, systemically applied, restores the bone inductive
capacity, microarchitecture, and quality of the skeleton in osteoporotic rats. Next, using
gene expression profiling, we found that BMP-6 exerts its osteoinductive effect at least
in part through the IGF-I and epidermal growth factor (EGF) pathways. (Grasser et al.,
2007) Hong et al. (2010) have studied impairment of osteoblasts differentiation in context
of the glucocorticoid-induced osteoporosis. They treated MC3T3-E1 cells with high dose of
dexamethasone, which inhibited cell differentiation and proliferation and induced apoptosis.
Authors used SILAC labelling with heavy/light lysine, SDS-PAGE protein separation and
nano LC coupled to LTQ-Orbitrap proteomic approach. They found upregulation of tubulins
(TUBA-1A, TUBB-2B, and TUBB-5), Ras GTPase-activating-like protein 1 (IQGAP1), S100
proteins (S100-A11, S100-A6, S100-A4, and S100-A10), myosins (MYH-9 and MYH-11), and
apoptosis and stress proteins (BAX), and downregulation of ATP synthases (ATP5O, ATP5H,
ATP5A1, and ATP5F1), G3BP-1, and Ras-related proteins (RAB-1A, RAB-2A, and RAB-7).
Hong et al. (2010a) have studied early osteoblast differentiation. They induced differentiation
of mouse osteoprogenitor MC3T3-E1 cells by rhBMP-2 and have studied cells in an early
differentiation stage critical for transformation of premature osteoblasts to mature osteoblasts.
At that stage osteoblasts express ALP but do not form mineralized nodules yet. By label-free
quantitative proteomic approach they identified numerous differentially expressed proteins
important for actin skeleton regulation and/or focal adhesion. They used SDS-PAGE proteins
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separation, and nano LC coupled to LTQ-Orbitrap peptide analysis. By western blot they have
confirmed upregulation of IQGAP1, isoform 1 of gelsolin (GSN), moesin, radixin, and cofilin 1
(CFL-1), and upregulation of focal adhesion proteins FLN-A, LAMA1, LAMA5, COL1A1,
COL3A1, COL4A6, and COL5A2, as well as the downregulation of COL4A1, COL4A2, and
COL4A4.
Park et al. (2009) have studied heparin-binding growth factor 2 (HBGF-2 ) effect on
osteoblasts. Authors used 2DE/MALDI-TOF proteomic approach. They identified
asparaginyl-tRNA synthetase (NARS), eukaryotic peptide chain release factor subunit 1
(ETF1), GDP-forming succinyl-CoA synthetase (SUCLG2), heat shock protein 84 (HSP 84),
sorting nexin 9 (SNX9) and neutral -glucosidase AB (GANAB) to be upregulated, and
tropomyosin 2 to be downregulated. NARS, member of aminoacyl-tRNA synthetases (AARS),
was upregulated more then 900 fold. NARS upregulation increased the cell proliferation.
NARS downregulation suppressed cell proliferation and induced cell apoptosis. Also
downregulation of NARS increased serum deprivation induced apoptosis. Reduction of
NARS also reduced p-Akt activity and increased caspase-3. Authors shown that HBGF-2
induced NARS promotes osteoblast survival through PI3K/Akt pathway.
Kodaira et al. (2006) have purified BMP-like factor from fetal bovine serum (FBS), which
they found to both inhibits myogenesis and stimulates differentiation of osteoblasts. They
started with 5 L of FBS, which they separated by heparin, strong anion exchange (SAX),
heparin again, strong cation exchange (SCX) and reverse phase chromatography. Using
LC-MS/MS authors identified this factor as BMP4, and found it to be in over 100 kDa complex
in circulation. Behnam et al. (2006) identified dermatopontin (DPT) as the most prominent
BMP-2 co-purified demineralized bone matrix protein, using alkaline urea extraction of BM,
separation of insoluble fraction by hydroxyapatite chromatography, SDS-PAGE of BMP active
fraction and MALDI-TOF analysis. Kubota et al. (2002) have studied signal transduction from
osteoclasts to osteoblasts. They have isolated and identified osteoblastogenesis inhibitory
factor (OBIF) from RANKL treated RAW264.7 cell line conditioned medium. This OBIF
inhibited osteoblastogenesis of MC3T3-E1 cell line, induced by BMP-4. After three step
chromatography (heparin affinity, anion exchange and reverse phase chromatography) from
1.8 L of conditioned medium, they have managed to identify OBIF as platelet-derived growth
factor BB (PDGF BB) homo-dimer using nano LC coupled to LCQ ion trap, working in data
dependant mode..
2.1.1 Chondrogenesis
Ji et al. (2010) have studied mesenchymal stem cells chondrogenesis. They induced
chondrogenic differentiation of C3H10T1/2 cells, murine embryonic mesenchymal cell line,
by treatment with BMP-2. They validated chondrogenesis by following glycosaminoglycan
and collagen type II. By isobaric tags for relative and absolute quantitation (iTRAQ) labeling
and 2D nano LC-MS/MS (QSTAR XL) analysis they identified 100 differentially expressed
proteins out of 1753 identified and quantified proteins. 83 proteins were downregulated,
and 17 upregulated. This is in concordance with “stem state” concept, which assumes wider
set of proteins expressed in cells which are less differentiated. Collagen types II and XI are
upregulated, as are PAPSS 2 and LOX, enzymes involved in posttraslational modification of
chondrocytes extracellular matrix components. Most enriched category of downregulated
proteins is energy metabolism. Chondrocytes produce ATPs by anaerobic glycolysis, because
cartilage is avascular and hypoxic. IGF-I was upregulated and was shown to exhibit additive
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effect on chondrogenesis with BMP-2. Fibulin-5, an ECM protein, was upregulated. BTF3L4,
general transcription factor, was upregulated. Kim et al. (2010) have studied chondrogenesis
of adipose tissue-derived stem cells (ASCs). They identified 756 proteins using nano LC
coupled to LCQ MS/MS approach. From 33 chondrogenic factors or proteins identified
authors especially mentioned type 2 collagen, biglycan, IGF-binding protein and TGF- 1.
2.2 Stem cells
One of the approaches in the regenerative medicine is the use of stem cells as cell therapies.
(Keller, 2005; Murry & Keller, 2008; Wobus & Boheler, 2005) Their self renewal capability,
the unlimited potential for differentiation, and signals that control differentiation fate are
under broad scientific scrutiny. We have reviewed the role of BMP-6 in mesenchymal stem
cell differentiation. (Vukicevic & Grgurevic, 2009) BMP-6 roles have been reviewed in bone
remodeling, bone to pancreas coupling and kidney development.
Lee et al. (2010) have studied BMP-2 induced differentiation of bone marrow stem cells
(BMSC). They identified and quantified 449 proteins using SILAC LC-MS/MS approach.
Proteins were separated by SDS-PAGE and in gel digested. Peptides were separated by
LC and analysed by LTQ-FT, working in the data dependant mode. Top five signals from
the survey scan were measured in the FT analyser using SIM, and CID fragmented in the
linear IT. 12 proteins were upregulated, 7 proteins were downregulated, and 19 proteins
were only detected in BMP-2 induced cells. Authors singled out -catenin (identified only
in BMP-2 induced differentiated cells with 4 peptides). Wnt/ -catenin pathway is known to
be important in osteoblast differentiation. They ruled out Smad and ERK BMP pathways on
-catenin upregulation. They identified PI3K pathway as crucial for BMP-2 induced BMSC
differentiation. Willert et al. (2003) have for the first time isolated Wnt3a in an active form.
They have expressed Wnt3a in mouse L cells, purified it from 2 L of conditioned medium by
three step chromatography (Blue sepharose, gel filtration and heparin cation exchange) in the
presence of CHAPS, due to hydrophobic nature of the Wnt protein. They have pinpointed
hydrophobicity to lipid modification, and have identified cysteine 77 as place of palmitation,
by MudPIT.
Hoof et al. (2009) studied phosphorylation dynamics during BMP4 induced differentiation
of hESCs. They used SILAC labeling and phosphopeptide enrichment by SCX-TiO2
chromatography. High resolution Orbitrap, working in the data dependant top two mode,
was used for the measurement of peptides in four time points (0, 30, 60, 240 min). Authors
identified 5222 proteins, of which 1399 were phosphorylated on 3067 sites (2431 serines, 582
threonines, and 54 tyrosines). Half of the quantified phosphopeptides are regulated within
the first hour of BMP-4 initiated differentiation. 586 identified proteins are regulated by the
core transcriptional network. By a GO analysis prominent protein groups are associated
with the epigenetic modification, transcription and translation. Authors found increased
phosphorylation of SMADs, PI3K/AKT pathway activation and transient activation of JNKs.
Regulators of pluripotency are also altered, but SOX2 did not changed its phosphorylation
status. By analysis of the predicted kinases responsible for measured phosphorylation,
authors found that CDK1/2 has central role.
Yocum et al. (2008) have identified and verified several potential markers of noggin-induced
neural and BMP-4-induced epidermal ectoderm differentiation of hESCs. They developed
hESCs cell culture system (on gelatin-coated dishes) free of mouse embryonic fibroblasts
(MEF) feeder layer or conditioned media. In this way targeted proteome is not contaminated
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by proteins from MEFs and noggin/BMP4 effect on hESCs is not influenced by possible
MEFs response. They used 2D LC/MALDI-TOF/TOF (ABI 4800 TOF/TOF) for global
analysis and MRM on 4000 Q Trap for verification and targeted analysis. Beside verification
of tubulin -III and cytokeratin-8, previously known markers for neuronal and epithelial
differentiation respectively, they proposed nuclear autoantigenic sperm protein (NASP) as
marker for pluripotency and dihydropyrimidinase-related protein (DRP) 2 and 4 as markers
for the early neuronal differentiation.
Nunomura et al. (2005) have identified 200 membrane proteins from mouse embryonic stem
cells using biotin based cell surface labeling, biotin-avidin affinity peptide purification
and 2D LC-MS/MS analysis on Q-Tof 2. Among 82 proteins involved in different cell
signaling pathways, they identified leukemia inhibitory factor receptor (LIF-R), interleukin-6
receptor subunit (IL-6R ), ciliary neurotrophic factor receptor (CNTFR- ), BMPR-1a and
integrin 6 1.
Prowse et al. (2005) identified 102 proteins secreted by human neonatal fibroblasts, which
are used for maintenance of undifferentiated growth of human embryonic stem cells, using
2D LC-MS and 2DE/MALDI-TOF. Among others they have identified proteins involved
in cell adhesion, cell proliferation and inhibition of cell proliferation, Wnt signaling and
inhibition of BMPs.
Kurisaki et al. (2005) have studied effects of the removal of leukemia inhibitory factor (LIF)
from mouse embryonic stem cells. LIF maintains pluripotency of mouse ESCs, by activating
JAK/STAT3 pathway. Only in cooperation with BMPs, can LIF inhibit differentiation of mouse
ESCs. BMPs activate expression of Id genes and suppress neuronal differentiation. Authors
identified more then 100 proteins by DIGE and MALDI-TOF analysis on AXIMA-CFR Plus
and/or 4700 Proteomics Analyzer.
2.3 Cancer
BMPs, as part of the TGF- protein superfamily, are involved in the cancer
patophysiology. (Massague, 2008) Klose et al. (2011) have shown BMP-7 induced cell
cycle arrest at G1/S checkpoint of human glioma-derived Gli36 EGFR-LITG cells. Kim et al.
(2009) have studied PRL-3-mediated metastasis using B16 and B16F10 mouse melanoma
cell lines. Using 2D DIGE and MS they identified the heat shock protein 70, fascin-1,
septin-6, ATP synthase beta subunit, and bone morphogenetic protein receptor type IB,
as proteins that differ in cancer cells with low and high metastatic potential. We showed
the inhibitory role of BMP-7 to bone metastases of breast cancer (Buijs et al., 2007) and
prostate cancer (Buijs et al., 2007a). The cancer metastasis can be triggered by TGF-
stimulating epithelial-to-mesenchymal transition. Recombinant BMP-7 is inhibiting cancer
bone metastases growth, so we proposed it as novel therapy for bone metastases. Rivera et al.
(2007) have identified 43 differentially expressed proteins in melanoma cell line with breast
cancer metastasis-suppressor 1 (BRMS1) gene silenced or over-expressed compared to wild
type. They used 2D-DIGE for relative quantification and MALDI-TOF/TOF (ABI 4800
TOF/TOF Analyzer) for protein identification from preparative 2D gel. Among others they
identified and confirmed BMPR-II. van Gils et al. (2005) reviewed serum and urine markers
in European prostate cancer P-Mark project. BMP-6 was considered as bone metastasis
prognostic serum marker, but later dismissed due to technical challenges in BMP-6 serum
detection. Cheung et al. (2004) have identified 24 kDa SELDI-TOF signal specific to early
prostate carcinogenesis as dimeric form of mature GDF-15. By laser capture micro-dissection
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(LCM) they have isolated normal, early cancer (Gleason grade 2 to 4) and high-grade prostatic
intraepithelial neoplasia (hPIN) epithelial cells from 22 patients. For SELDI-TOF analysis,
authors used a copper IMAC chemistry, and proteins measured by Ciphergen Protein Biology
System II spectrometer (Ciphergen Biosystems, Inc.). For the protein identification, authors
first separated proteins by SDS-PAGE. 24 kDa band was analysed by oMALDI Q-TOF (ABI
Q-Star).
2.4 Kidney
We have previously reviewed the role of BMPs on the development and homeostasis of
kidneys. (Simic & Vukicevic, 2005) BMPs have been connected to kidney biology already in
1990s. The BMPs role in kidney development has been discovered by early localization studies
using immunohistochemistry (Vukicevic et al., 1994a), autoradiography (Vukicevic et al.,
1990) and in situ hybridization (Helder et al., 1995; Vukicevic et al., 1994). We have shown that
BMP-7 is crucial for metanephric mesenchyme differentiation during kidney development.
(Vukicevic et al., 1996)
BMP-7 is effective in treatment of acute renal failure, as we have shown in a
ishemia/reperfusion rat model. (Vukicevic et al., 1998) Wang & Hirschberg (2011) have
identified Y-box protein-1 (YB-1) as BMP-7 transcriptional activator in context of chronic
kidney disease (CKD) using LC-MS/MS. They used promotor region of BMP7 gene to fish out
factors from MDCK nuclear fraction. Proteins were separated by SDS-PAGE, and analysed
by nano LC coupled to LTQ-Orbitrap XL. We have identified BMP-6, GDF-15 and BMP-1-3
from plasma of healthy volunteers and patients with CKD. (Grgurevic et al., 2011a) We
showed an increased renal fibrosis in rats with CKD after systemic administration of BMP-1-3.
Administration of anti BMP-1-3 antibody reduced the fibrosis.
2.5 Iron
Iron content is tightly controlled by individual cell and also systemically by hole organism.
(Hentze et al., 2004; 2010) We found that BMP-6 is an endogenous regulator of iron
metabolism in vivo. (Andriopoulos et al., 2009) Bmp6 knockout mouse has reduced hepcidin
expression and tissue iron overload, which resembles hemochromatosis. Hepcidin has
a central role in maintaining iron body levels. Recombinant BMP6, when administered
to mouse with hemochromatosis reduced the serum iron in a dose-dependent manner.
Next, we found that BMP-6 treatment reduces hemochromatosis in Hfe knockout mouse.
(Corradini et al., 2010) We also showed BMP-6 effect on TMPRSS6 expression, which is a
negative regulator of hepcidin. (Meynard et al., 2011)
Kartikasari et al. (2008) used SELDI-TOF MS to detect and quantify hepcidin-25, 25 residues
long hepcidin isoform which regulates the iron homeostasis. Authors used cation exchange
chip for protein binding, and Ciphergen Protein Biology System IIc TOF mass spectrometer
for the measurements. They found synergistic upregulation of hepcidin-25 by BMP-2/9 and
IL-6, suggesting a crosstalk between iron and inflammatory pathways.
2.6 Other
BMP-15 is oocyte secreted growth factor important for female fertility. (Elvin et al., 2000)
Saito et al. (2008) have characterized rhBMP-15 expressed in human embryonic kidney 293
cells by MS. Authors used MALDI-TOF (Reflex 3, Bruker) for the protein molecular weight
measurement and micro LC coupled to LTQ-Orbitrap for the CID fragmentation and the
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neutral loss measurements. They found N-terminal amino acid to be pyroglutamic acid and
C-terminal end to be truncated. 16 kDa BMP-15 form is phosphorylated on serine 6 and
17 kDa BMP-15 form is O-glycosilated on threonine 10. Tibaldi et al. (2010) have identified
serine 6 from mature BMP-15 and BMP-9 to be phosphorylated by Golgi apparatus casein
kinase (G-CK). Phosphorylation sites were identified using phosphopeptide enrichment and
nano LC coupled to LCQ XL, or MALDI-TOF/TOF (ABI 4800 Plus) analysis.
Li et al. (2007) have studied ubiquitination of Smad1 mediated by carboxyl terminus of
Hsc70-interacting protein (CHIP). They have confirmed N-termus mono-ubiquitination of
Smad1 by MALDI-TOF analysis of in vitro ubiquinated Smad1.
Pulmonary arterial hypertension (PAH) was reviewed by Rubin (1997) and Rabinovitch
(2008). Abdul-Salam et al. (2010) found 25 differentially expressed out of more than 300
identified proteins by SDS-PAGE and LC-MS/MS from lung tissue of 8 patients and 8
control subjects. They found for the first time increased expression of chloride intracellular
channel 4 (CLIC4), receptor for advanced glycation end products, and periostin. Meyrick et al.
(2008) found 16 differentially expressed proteins in familial pulmonary arterial hypertension
(FPAH) patients compared to obligate carrier from the same family with known BMPR-2
mutation. They used 2D-DIGE/MALDI-TOF(/TOF) of EBV-transformed B lymphocytes.
They connected adapter protein growth factor receptor bound protein (GRB2) to signal
transduction of BMPR-2 receptor.
Pappano et al. (2003) have identified in vivo substrates of BMP-1 and mammalian Tolloid-like
metalloproteinases (mTLL) using proteomics. They compared in vivo procollagen
C-proteinase (pCP) activity of wild type vs Bmp1 Tll doubly homozygous null mice. Using
nano ESI-QTof sequencing, they have identified four 2DE spots (absent in Bmp1–/– Tll–/–
mouse embryo fibroblasts, MEF, conditioned media) as C-propeptides of the pro 1 chain of
type I procollagen, of the pro 1 chain of type III procollagen, of the pro 2 chain of type III
procollagen and for the first time proline- and arginine-rich protein (PARP) subdomain of the
N-terminal globular sequences of the pro 1 chain of type XI collagen.
The low resolution structure of procollagen C-proteinase enhancer 1 (PCPE-1), an extracellular
matrix glycoprotein that can stimulate the pCP action of tolloid metalloproteinases, was
determined by Bernocco et al. (2003). Using MALDI-TOF they have determined MW of
PCPE-1 to be 48628 Da. Wajih et al. (2004) have studied intracellular processing and transport
of the matrix -carboxyglutamic acid protein (MGP) in human vascular smooth muscle cells
(VSMCs) infected with adenovirus carrying the MGP construct. MGP is an inhibitor of arterial
wall and cartilage calcification through the binding of BMP-2. They have identified bovine
fetuin instead of MGP using SDS-PAGE followed by nano LC coupled to LCQ Deca XL
ion trap MS. Using glutathion-S-transferase (GST) pull-down followed by 2DE/MALDI-TOF
analysis, Hassel et al. (2004) identified 33 proteins interacting with BMPRII. Wermter et al.
(2007) studied the substrate selectivity of BMP-1 using the full-length vs. isolated proteolytic
domain of BMP-1. They managed to over-express BMP-1 catalytic domain in E. coli and
to refold it properly. By MALDI-TOF analysis of reduced vs. unreduced tryptic peptides
they confirmed the proper formation of three disulphide bridges (C65-C85, C43-C199 and
C63-C66). Number of ligands that are binding to activin type II receptor (ActRII) and ActRIIB
from human and mouse sera have been identified using affinity purification, SDS-PAGE and
nano LC coupled to linear IT (LTQ). (Souza et al., 2008) They confirmed that in addition to
myostatin, BMP-11 and activins-A, -B and -AB could regulate the muscle growth by inhibiting
myblast-to-myotube differentiation. Meleady et al. (2008) have compared Chinese hamster
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ovary (CHO) cells expressing rhBMP-2 to cell co-expressing soluble exogenous paired basic
amino acid cleaving enzyme (PACEsol), which improves post-translational processing of the
mature rhBMP-2. They used 2D-DIGE/MALDI-TOF and found 60 differentially expressed
proteins.
3. Conclusion
Growth factors MS based characterization from biofluids is almost exclusively done by CID
on plethora of different tandem instruments. Very low levels of growth factors in circulation is
limiting their MS based identification due to huge dynamic range of plasma/serum proteins.
Different biochemical purification strategies are used to enrich individual growth factors
enough to be able to analyse it by MS. Most of them use heparin affinity chromatography as
one purification step. We have successfully identified number of growth factors from biofluids
using heparin based enrichment, followed by the SDS-PAGE protein separation and peptide
analysis on nano LC coupled to LTQ-Orbitrap.
4. Future prospects
Disparity between liters of starting material used in the isolation and identification studies of
individual growth factors from biological fluids, and an unmet need to use small amounts of
biological samples for high throughput clinically relevant studies, is ending by development
of growth factors enrichment strategies and of course by development of new and better mass
spectrometers, and/or new proteomic strategies.
In the future we can expect more and more proteomic studies with BMPs and other growth
factors to be identified, quantified and/or characterized from different clinically relevant
samples. This will help to better understand particular diseases, discover new biomarkers
and to develop new therapeutic strategies.
5. Abrreviations
2DE Two dimensional gel electrophoresis
ig-h3 Transforming growth factor- -induced protein ig-h3 ( ig-h3)
(Kerato-epithelin) (RGD-containing collagen-associated protein) (RGD-CAP)
AARS Aminoacyl-tRNA synthetases
ARTN Artemin (Enovin) (Neublastin)
ASC Adipose tissue-derived stem cells
ATP5F1 ATP synthase B chain, mitochondrial precursor
ATP5H ATP synthase D chain, mitochondrial
ATP5O ATP synthase O subunit, mitochondrial precursor
ATPA1 ATP synthase subunit alpha, mitochondrial precursor
BAX Apoptosis regulator BAX
bFGF Heparin-binding growth factor 2 (HBGF-2) (Basic fibroblast growth factor)
(bFGF)
BMP Bone morphogenetic protein
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BMP-1 Bone morphogenetic protein 1 (BMP-1) (EC 3.4.24.19) (Mammalian tolloid
protein) (mTld) (Procollagen C-proteinase) (PCP)
BMP-10 Bone morphogenetic protein 10 (BMP-10)
BMP-15 Bone morphogenetic protein 15 (BMP-15) (Growth/differentiation factor 9B)
(GDF-9B)
BMP-2 Bone morphogenetic protein 2 (BMP-2) (Bone morphogenetic protein 2A)
(BMP-2A)
BMP-3 Bone morphogenetic protein 3 (BMP-3) (Bone morphogenetic protein 3A)
(BMP-3A) (Osteogenin)
BMP-3B Bone morphogenetic protein 3B (BMP-3B) (Bone-inducing protein) (BIP)
(Growth/differentiation factor 10) (GDF-10)
BMP-4 Bone morphogenetic protein 4 (BMP-4) (Bone morphogenetic protein 2B)
(BMP-2B)
BMP-5 Bone morphogenetic protein 5 (BMP-5)
BMP-6 Bone morphogenetic protein 6 (BMP-6) (VG-1-related protein) (VG-1-R)
(VGR-1)
BMP-7 Bone morphogenetic protein 7 (BMP-7) (Osteogenic protein 1) (OP-1)
(Eptotermin )
BMP-8A Bone morphogenetic protein 8A (BMP-8A)
BMP-8B Bone morphogenetic protein 8B (BMP-8) (BMP-8B) (Osteogenic protein 2)
(OP-2)
BMPR-II Bone morphogenetic protein receptor type-2 (BMP type-2 receptor) (BMPR-2)
(EC 2.7.11.30) (Bone morphogenetic protein receptor type II) (BMP type II
receptor) (BMPR-II)
BMSC Bone marrow stem cell
BRMS1 Breast cancer metastasis-suppressor 1
BTF3L4 Transcription factor BTF3 homolog 4 (Basic transcription factor 3-like 4)
C3H10T1/2 Murine embryonic mesenchymal cell line
CDK1 Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division
control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
CFL-1 Cofilin-1 (18 kDa phosphoprotein) (p18) (Cofilin, non-muscle isoform)
CHIP E3 ubiquitin-protein ligase CHIP (EC 6.3.2.-) (Antigen NY-CO-7)
(CLL-associated antigen KW-8) (Carboxy terminus of Hsp70-interacting
protein) (STIP1 homology and U box-containing protein 1)
CID Collision induced dissociation
CKD Chronic kidney disease
CLIC4 Chloride intracellular channel protein 4 (Intracellular chloride ion channel
protein p64H1)
CNTFR- Ciliary neurotrophic factor receptor subunit (CNTF receptor subunit )
(CNTFR- )
COL1A1 Collagen -1(I) chain ( -1 type I collagen)
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CRMP-2 Dihydropyrimidinase-related protein 2 (DRP-2) (Collapsin response mediator
protein 2) (CRMP-2) (N2A3) (Unc-33-like phosphoprotein 2) (ULIP-2)
CRTAC1 Cartilage acidic protein 1 (68 kDa chondrocyte-expressed protein) (CEP-68)
(ASPIC)
Da Dalton
DBM Demineralized bone matrix
DIGE Difference gel electrophoresis
DPT Dermatopontin (Tyrosine-rich acidic matrix protein) (TRAMP)
DRP-2 Dihydropyrimidinase-related protein 2 (DRP-2) (Collapsin response mediator
protein 2) (CRMP-2) (N2A3) (Unc-33-like phosphoprotein 2) (ULIP-2)
EBV Epstein-Barr virus
EGF Epidermal growth factor
ESI Electrospray ionisation
ETF1 Eukaryotic peptide chain release factor subunit 1 (Eukaryotic release factor 1)
(eRF1) (Protein Cl1) (TB3-1)
FLN-A Filamin-A (FLN-A) (Actin-binding protein 280) (ABP-280) ( -filamin)
(Endothelial actin-binding protein) (Filamin-1) (Non-muscle filamin)
FT Fourier transform mass spectrometry
G3BP-1 Ras GTPase-activating protein-binding protein 1
GANAB Neutral -glucosidase AB (EC 3.2.1.84) ( -glucosidase 2) (Glucosidase II
subunit ) ( glucosidase 2 neutral subunit)
GDF Growth/differentiation factor
GDF-1 Embryonic growth/differentiation factor 1 (GDF-1)
GDF-11 Growth/differentiation factor 11 (GDF-11) (Bone morphogenetic protein 11)
(BMP-11)
GDF-15 Growth/differentiation factor 15 (GDF-15) (Macrophage inhibitory cytokine 1)
(MIC-1) (NSAID-activated gene 1 protein) (NAG-1) (NSAID-regulated gene
1 protein) (NRG-1) (Placental TGF- ) (Placental bone morphogenetic protein)
(Prostate derived factor)
GDF-2 Growth/differentiation factor 2 (GDF-2) (Bone morphogenetic protein 9)
(BMP-9)
GDF-3 Growth/differentiation factor 3 (GDF-3)
GDF-5 Growth/differentiation factor 5 (GDF-5) (Cartilage-derived morphogenetic
protein 1) (CDMP-1) (Radotermin)
GDF-6 Growth/differentiation factor 6 (GDF-6) (Growth/differentiation factor 16)
GDF-7 Growth/differentiation factor 7 (GDF-7)
GDF-8 Growth/differentiation factor 8 (GDF-8) (Myostatin)
GDF-9 Growth/differentiation factor 9 (GDF-9)
GDNF Glial cell line-derived neurotrophic factor (hGDNF) (Astrocyte-derived
trophic factor) (ATF)
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HBGF-2 Heparin-binding growth factor 2 (HBGF-2) (Basic fibroblast growth factor)
(bFGF)
hPIN High-grade prostatic intraepithelial neoplasia
HSP 84 Heat shock protein HSP 90- (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84)
ICAT Isotope-coded affinity tag
ICR Ion cyclotron resonance
IGF-I Insulin-like growth factor I (IGF-I) (Mechano growth factor) (MGF)
(Somatomedin-C)
IL-6R Interleukin-6 receptor subunit (IL-6 receptor subunit ) (IL-6R subunit
) (IL-6R- ) (IL-6R ) (Interleukin-6 signal transducer) (Membrane
glycoprotein 130) (gp130) (Oncostatin-M receptor subunit ) (CD antigen
CD130)
IMAC Immobilized metal ion affinity chromatography
INH Inhibin
INH- Inhibin chain
INH- -A Inhibin A chain (Activin -A chain) (Erythroid differentiation protein) (EDF)
INH- -B Inhibin B chain (Activin -B chain)
INH- -C Inhibin C chain (Activin -C chain)
INH- -E Inhibin beta E chain (Activin -E chain)
IQGAP1 Ras GTPase-activating-like protein 1
IT Ion trap
iTRAQ Isobaric tags for relative and absolute quantitation
LAMA1 Laminin subunit -1 (Laminin A chain) (Laminin-1 subunit ) (Laminin-3
subunit ) (S-laminin subunit ) (S-LAM )
LC Liquid chromatography
LC-MS/MS Liquid chromatography coupled to tandem mass spectrometry
LCM Laser capture microdissection
LCQ 3D ion trap from Thermo
LFTY1 Left-right determination factor 1 (Left-right determination factor B) (Protein
lefty-1) (Protein lefty-B)
LFTY2 Left-right determination factor 2 (Endometrial bleeding-associated factor)
(Left-right determination factor A) (Protein lefty-2) (Protein lefty-A)
(Transforming growth factor -4) (TGF- -4)
LIF Leukemia inhibitory factor
LIF-R Leukemia inhibitory factor receptor (LIF receptor) (LIF-R) (D-factor/LIF
receptor) (CD antigen CD118)
LOX Protein-lysine 6-oxidase (EC 1.4.3.13) (Lysyl oxidase)
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LTQ Linear trap quadrupole
MALDI Matrix assisted laser desorption/ionisation
MC3T3-E1 Mouse osteoblast precursor-like cell line
MEF Mouse embryo fibroblasts
MGP Matrix -carboxyglutamic acid protein
MIS Muellerian-inhibiting factor
MRM Multiple reaction monitoring
MS Mass spectrometry
MS/MS Tandem mass spectrometry
MS3 Triple stage mass spectrometry
MudPIT Multidimensional protein identification technology
MYH Myosin
NARS Asparaginyl-tRNA synthetase, cytoplasmic (EC 6.1.1.22) (Asparagine–tRNA
ligase) (AsnRS)
NASP Nuclear autoantigenic sperm protein
NODAL Nodal homolog
NRTN Neurturin
OBIF Osteoblastogenensis inhibitory factor
oMALDI Orthogonal MALDI
PAPSS 2 Bifunctional 3’-phosphoadenosine 5’-phosphosulfate synthase 2 (PAPS
synthase 2) (PAPSS 2) (Sulfurylase kinase 2) (SK 2) (SK2) [Includes:
Sulfate adenylyltransferase (EC 2.7.7.4) (ATP-sulfurylase) (Sulfate
adenylate transferase) (SAT); Adenylyl-sulfate kinase (EC 2.7.1.25)
(3’-phosphoadenosine-5’-phosphosulfate synthase) (APS kinase)
(Adenosine-5’-phosphosulfate 3’-phosphotransferase) (Adenylylsulfate
3’-phosphotransferase)]
PCPE-1 Procollagen C-endopeptidase enhancer 1 (Procollagen COOH-terminal
proteinase enhancer 1) (PCPE-1) (Procollagen C-proteinase enhancer 1)
(Type 1 procollagen C-proteinase enhancer protein) (Type I procollagen
COOH-terminal proteinase enhancer)
PDGF Platelet-derived growth factor
PMF Peptide mass fingerprint
PRL-3 Protein tyrosine phosphatase type IVA 3 (EC 3.1.3.48) (PRL-R)
(Protein-tyrosine phosphatase 4a3) (Protein-tyrosine phosphatase of
regenerating liver 3) (PRL-3)
PSPN Persephin (PSP)
Q-Tof Quadrupole time-of-flight mass spectrometer
QSTAR Q-Tof from Applied Biosystems
Q Trap Hybrid triple quadrupole/linear ion trap mass spectrometer
RAB-1A Ras-related protein Rab-1A (YPT1-related protein)
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RANKL Tumor necrosis factor ligand superfamily member 11 (Osteoclast
differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor
activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related
activation-induced cytokine) (TRANCE) (CD antigen CD254) [Cleaved
into: Tumor necrosis factor ligand superfamily member 11, membrane form;
Tumor necrosis factor ligand superfamily member 11, soluble form]
RAW264.7 Mouse osteoclast-like myeloma cell line
SAX Strong anion exchange
SCX Strong cation exchange
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SELDI Surface-enhanced laser desorption/ionization
SILAC Stable isotope labeling by amino acids in cell culture
SIM Single ion monitoring
SNX9 Sorting nexin-9 (SH3 and PX domain-containing protein 1) (Protein SDP1)
(SH3 and PX domain-containing protein 3A)
SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit , mitochondrial (EC 6.2.1.4)
(GTP-specific succinyl-CoA synthetase subunit ) (Succinyl-CoA synthetase
-G chain) (SCS- G)
TGF- Transforming growth factor
TGF- -1 Transforming growth factor -1 (TGF- -1) [Cleaved into: Latency-associated
peptide (LAP)]
TGF- -2 Transforming growth factor beta-2 (TGF- -2) (BSC-1 cell growth inhibitor)
(Cetermin) (Glioblastoma-derived T-cell suppressor factor) (G-TSF)
(Polyergin)
TGF- -R-3 Transforming growth factor receptor type 3 (TGF- receptor type 3)
(TGF-R-3) ( glycan) (Transforming growth factor receptor III) (TGF-
receptor type III)
Th Thomson
TMPRSS6 Transmembrane protease serine 6 (EC 3.4.21.-) (Matriptase-2)
TOF/TOF Tandem time-of-flight mass spectrometry
VSMC Vascular smooth muscle cells
YB-1 Nuclease-sensitive element-binding protein 1 (CCAAT-binding transcription
factor I subunit A) (CBF-A) (DNA-binding protein B) (DBPB) (Enhancer factor
I subunit A) (EFI-A) (Y-box transcription factor) (Y-box-binding protein 1)
(YB-1)
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